See All Slides -

Slides

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Left Main Stenting: Fascinating Cases and Lessons From the EXCEL Angiographic Core Lab

Presenter: David E. Kandzari, Jens Flensted Lassen, Philippe Généreux

October 30, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

A Predictable Complication (In retrospect) and A Great Save: When Transradial Goes Wrong

Presenter: Francesco Burzotta, Shigeru Saito, Mauricio G. Cohen

October 30, 2016

Presentation TCT 2016

Beyond Hypertension: Autonomic Modulation Therapies for Arrhythmias

Presenter: Elazer R. Edelman, Krishna J. Rocha-Singh, Vivek Y. Reddy

October 30, 2016

Presentation TCT 2016

What Is the Best Treatment for the End-stage Heart Failure Patient With Severe FMR? Stop Wasting Valuable Time Go Straight to LVAD/Transplant!

Presenter: Alec S. Vahanian, Ralph Stephan von Bardeleben, Nir Uriel

October 30, 2016

Presentation TCT 2016

Case Presentation: A Surprise in the Evaluation and Management of Stent Thrombosis

Presenter: Fernando Alfonso, Stephan Windecker, Ehrin J. Armstrong

October 30, 2016

Presentation TCT 2016

Valve-in-Valve Therapies - Not Just a Russian Doll! Technical and Clinical Challenges: Engineering Perspectives

Presenter: Carlos E. Ruiz, Ulrich Steinseifer, Ajit Yoganathan

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research II: Updates From the UK TAVR Registry

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Neil E. Moat

October 30, 2016

Presentation TCT 2016

Mediation Analysis: A Method to Assign Attributable Risk

Presenter: Scott Berry, Stuart J. Pocock, Bjorn Redfors

October 30, 2016

Advertisement

Slides

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Left Main Stenting: Fascinating Cases and Lessons From the EXCEL Angiographic Core Lab

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

A Predictable Complication (In retrospect) and A Great Save: When Transradial Goes Wrong

Beyond Hypertension: Autonomic Modulation Therapies for Arrhythmias

What Is the Best Treatment for the End-stage Heart Failure Patient With Severe FMR? Stop Wasting Valuable Time Go Straight to LVAD/Transplant!

Case Presentation: A Surprise in the Evaluation and Management of Stent Thrombosis

Valve-in-Valve Therapies - Not Just a Russian Doll! Technical and Clinical Challenges: Engineering Perspectives

Key Contributions to TAVR Clinical Research II: Updates From the UK TAVR Registry

Mediation Analysis: A Method to Assign Attributable Risk

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content